NCT05887934 is a clinical trial of X-Ray Fluorescence Analyzer in Lead Exposure, sponsored by Medical University of South Carolina.

Who is sponsoring NCT05887934?

NCT05887934 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT05887934?

Interventions in NCT05887934: X-Ray Fluorescence Analyzer.

What condition does NCT05887934 study?

NCT05887934 studies Lead Exposure.

Is NCT05887934 still recruiting?

NCT05887934 is currently enrolling by invitation. Last updated 14 October 2025.

Last reviewed 2025-10-14 · How we verify

NCT05887934

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bone-Lead Level Associations With Brain and Mental Health

ENROLLING BY INVITATION Last updated 14 October 2025

What this trial tests

trial testing X-Ray Fluorescence Analyzer in Lead Exposure in 500 participants. Enrolling by invitation.

Timeline

17 August 2023

Primary endpoint
1 May 2027

1 May 2027

Quick facts

Lead sponsor	Medical University of South Carolina
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	500
Start date	17 August 2023
Primary completion	1 May 2027
Estimated completion	1 May 2027
Sites	1 location across United States

Drugs / interventions tested

X-Ray Fluorescence Analyzer

Conditions studied

Lead Exposure — all drugs for Lead Exposure →

Sponsor

Medical University of South Carolina

Who can join

Adults 18 to 70, any sex, with Lead Exposure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to assess cumulative lead exposure among treatment-seeking patients in the MUSC hospital system receiving experimental transcranial magnetic stimulation (TMS), transcranial direct-current stimulation (tDCS), an electroencephalogram (EEG), and/or transcutaneous auricular vagus nerve stimulation (taVNS) therapies to determine whether lead exposure represents a risk factor for more severe mental illness or a modifier of treatment response. Information will be obtained from patients with a variety of neuropsychiatric disorders recruited to existing hospital studies. This information will include the results of bone-lead testing, brief cognitive tests, and self-reported psychiatric symptoms and behaviors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05887934 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 14 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05887934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing